Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis

Oncogene

Volumn 33, Issue 26, 2014, Pages 3473-3484

  Wang, C ^a   Li, Y ^a   Zhang, H ^a   Liu, F ^a   Cheng, Z ^a   Wang, D ^a   Wang, G ^a   Xu, H ^a   Zhao, Y ^a   Cao, L ^a   Li, F ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

gastric cancer; PAK4; Smad2; Smad3; TGF b

Indexed keywords

P21 ACTIVATED KINASE 4; PHOSPHOTRANSFERASE; PROTEASOME; SCATTER FACTOR; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN; P21 ACTIVATED KINASE; PAK4 PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; GENE REPRESSION; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSACTIVATION; ADULT; AGED; BIOSYNTHESIS; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; STOMACH TUMOR;

ADULT; AGED; CARCINOGENESIS; CELL LINE; CELL PROLIFERATION; FEMALE; HEK293 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; P21-ACTIVATED KINASES; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903626071     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.300     Document Type: Article

References (59)

1. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258.
2. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153.
3. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
4. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693.
5. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-230.
6. Yang L, Moses HL. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 2008; 68: 9107-9111.
7. Itoh S, Itoh F. Inhibitory machinery for the TGF-beta family signaling pathway. Growth Factors 2011; 29: 163-173.
8. Liu T, Feng XH. Regulation of TGF-beta signalling by protein phosphatases. Biochem J 2010; 430: 191-198.
9. Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141: 1167-1178.
10. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
11. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000; 19: 1745-1754.
12. Drabsch Y, Ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 2012; 31: 553-568.
13. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Shan B. Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma. Mol Biol Rep 2012; 39: 9453-9462.
14. Ijichi H, Ikenoue T, Kato N, Mitsuno Y, Togo G, Kato J et al. Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. Biochem Biophys Res Commun 2001; 289: 350-357.
15. Shitara Y, Yokozaki H, Yasui W, Takenoshita S, Kuwano H, Nagamachi Y et al. No mutations of the Smad2 gene in human sporadic gastric carcinomas. Jpn J Clin Oncol 1999; 29: 3-7.
16. Han SU, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 2004; 23: 1333-1341.
17. Li X, Liu F, Li F. PAK as a therapeutic target in gastric cancer. Expert Opin Ther Targets 2010; 14: 419-433.
18. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006; 6: 459-471.
19. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 2009; 28: 209-217.
20. Minden A. PAK4-6 in cancer and neuronal development. Cell Logist 2012; 2: 95-104.
21. Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA 2008; 105: 19372-19377.
22. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 2002; 277: 550-558.
23. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY et al. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci USA 2010; 107: 18622-18627.
24. Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY et al. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis 2011; 32: 765-771.
25. Li Z, Xu HM, Li F. Expression of PAK4 and its significance in gastric cancer. Chinese J Oncol 2008; 30: 30-33.
26. Li X, Ke Q, Li Y, Liu F, Zhu G, Li F. DGCR6L, a novel PAK4 interaction protein, regulates PAK4-mediated migration of human gastric cancer cell via LIMK1. Int J Biochem Cell Biol 2010; 42: 70-79.
27. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997; 272: 28107-28115.
28. Wells CM, Abo A, Ridley AJ. PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci 2002; 115: 3947-3956.
29. Wells CM, Whale AD, Parsons M, Masters JR, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci 2010; 123: 1663-1673.
30. Orian A, Eisenman RN. TGF-beta flips the Myc switch. Sci STKE 2001; 88: pe1.
31. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 2004; 24: 2546-2559.
32. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci USA 2000; 97: 9498-9503.
33. Warner BJ, Blain SW, Seoane J, Massague J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol 1999; 19: 5913-5922.
34. Bauer J, Sporn JC, Cabral J, Gomez J, Jung B. Effects of activin and TGFbeta on p21 in colon cancer. PLoS One 2012; 7: e39381.
35. Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem 2001; 276: 14414-14419.
36. Gnesutta N, Minden A. Death receptor-induced activation of initiator caspase 8 is antagonized by serine/threonine kinase PAK4. Mol Cell Biol 2003; 23: 7838-7848.
37. Li X, Minden A. PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival pathways by facilitating TRADD binding to the TNF receptor. J Biol Chem 2005; 280: 41192-41200.
38. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGFbeta family signalling. Nature 2003; 425: 577-584.
39. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-816.
40. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 1999; 274: 37413-37420.
41. Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J et al. CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. J Immunol 2009; 182: 1810-1817.
42. Seong HA, Jung H, Kim KT, Ha H. 3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with Smad proteins. J Biol Chem 2007; 282: 12272-12289.
43. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res 2009; 19: 8-20.
44. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB et al. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 1998; 12: 1587-1592.
45. Dai C, Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGFbeta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 2004; 15: 1402-1412.
46. Shukla MN, Rose JL, Ray R, Lathrop KL, Ray A, Ray P. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009; 40: 643-653.
47. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004; 23: 7416-7429.
48. Yan X, Zhang J, Sun Q, Tuazon PT, Wu X, Traugh JA et al. p21-Activated kinase 2 (PAK2) inhibits TGF-beta signaling in Madin-Darby canine kidney (MDCK) epithelial cells by interfering with the receptor-Smad interaction. J Biol Chem 2012; 287: 13705-13712.
49. Wu Y, Li Q, Zhou X, Yu J, Mu Y, Munker S et al. Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer. PLoS One 2012; 7: e35684.
50. Ahn HK, Jang J, Lee J, Se Hoon P, Park JO, Park YS et al. P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Transl Oncol 2012; 4: 345-349.
51. Jonckheere N, Perrais M, Mariette C, Batra SK, Aubert JP, Pigny P et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene 2004; 23: 5729-5738.
52. Shimada K, Suzuki N, Ono Y, Tanaka K, Maeno M, Ito K. Ubc9 promotes the stability of Smad4 and the nuclear accumulation of Smad1 in osteoblast-like Saos- 2 cells. Bone 2008; 42: 886-893.
53. Suganuma T, Kawabata M, Ohshima T, Ikeda MA. Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci USA 2002; 99: 13073-13078.
54. Lee BH, Chen W, Stippec S, Cobb MH. Biological cross-talk between WNK1 and the transforming growth factor beta-Smad signaling pathway. J Biol Chem 2007; 282: 17985-17996.
55. Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F et al. ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells. Oncogene 2006; 25: 5591-5600.
56. Li Y, Shao Y, Tong Y, Shen T, Zhang J, Gu H et al. Nucleo-cytoplasmic shuttling of PAK4 modulates beta-catenin intracellular translocation and signaling. Biochim Biophys Acta 2012; 1823: 465-475.
57. Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H et al. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett 2012; 317: 24-32.
58. Liu F, Li X, Wang C, Cai X, Du Z, Xu H et al. Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer 2009; 125: 2511-2519.
59. Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RB et al. Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res 1989; 49: 2091-2095.